Skip to main content
. 2024 Nov 29;6(6):fcae433. doi: 10.1093/braincomms/fcae433

Table 1.

Demographics and clinical features of the study cohort

  Control svPPA lvPPA nfvPPA PSP CBS P*
N 24 9 9 9 10 13 -
Age (SD) 65.8 (5.2) 67.2 (4.3) 68.9 (8.1) 70.1 (6.4) 68.4 (5.9) 70.2 (4.4) ns
Gender M:F 11:13 5:4 6:3 4:5 5:5 7:6 ns
Handedness R:L 21:3 9:0 9:0 8:1 9:1 12:1 ns
Ethnicity white:other 24:0 9:0 9:0 9:0 9:0 9:0 -
First language English:other 24:0 9:0 9:0 8:1 9:0 9:0 -
Age left education (SD) 20.6 (3.3) 19.3 (2.6) 20.6 (4.1) 16.6 (1.7) 16.7 (1.7) 17.4 (3.0) <0.001
Symptom duration in years (SD) NA 6.5 (2.5) 3.0 (2.7) 3.2 (2.9) 4.1 (2.5) 5.2 (4.0) ns
Total MLSE (SD) 98.3 (2.2) 78.1 (4.7) 68.1 (15.3) 70.9 (15.5) 87.9 (8.0) 81.8 (14.3) <0.001
ACE-R (SD) 96.0 (3.4) 53.9 (8.2) 46.7 (25.1) 69.7 (15.1) 80.5 (13.4) 74.0 (17.6) <0.001

Note: Mean and standard deviations are displayed. For MLSE and ACE-R, values indicate scores out of 100. *P-value for F-test of group difference by ANOVA. ACE-R, Addenbrooke’s Cognitive Examination Revised; CBS, corticobasal syndrome; lvPPA, logopenic variant primary progressive aphasia; MLSE, Mini Linguistic State Examination; nfvPPA, non-fluent variant primary progressive aphasia; ns, not significant, P > 0.1; PSP, progressive supranuclear palsy; SD, standard deviation; svPPA, semantic variant primary progressive aphasia.